Research & Clinical Trials
Concerning COVID-19 Only
All the advancements in preventing and treating COVID-19 are due to the brave volunteers who entered clinical trials for vaccines, monoclonal antibodies for both treatment and prevention, and antivirals. Here you will find both the results of important trials giving us the information needed to best navigate the pandemic and information about appropriate open trials that offer access to new cutting-edge therapies.
ADDITIONAL READING
Don Diamond. Ph.D., has been working for decades at City of Hope, Duarte, CA, constructing a new vaccine platform that will benefit the immunocompromised. It’s already been successfully used in post allogeneic hematopoietic stem cell (bone marrow) transplants to prevent a different viral infection, CMV.
On October 11, 2021, AstraZeneca announced the topline results from their Phase III TACKLE trial in outpatient treatment with AZD7442 for patients with early, mild to moderate COVID-19.
I am introducing eight different research articles and commentaries on COVID-19 that are pertinent to the chronic lymphocytic community, and have informed my personal and institutional response to the demands and opportunities afforded by being one of the most vulnerable during a world-changing pandemic over the past weeks. You
This is the first study to show that pre-exposure prophylaxis, (PReP), with a mix of a long acting intramuscular (IM) injection of anti-COVID-19 monoclonal antibodies (AZD7442) is not only protective, significantly, it is protective in a high-risk population where “more than 75% of participants had co-morbidities, which include conditions
At the annual meeting of the American Society of Hematology (ASH) 2020, our own Dr. Brian Koffman interviewed Dr. Lindsey Roeker, a hematologic oncologist at Memorial Sloan Kettering Cancer Center. They discussed new data looking at COVID-19 vaccine response in patients with CLL.
Research pertaining to when CLL meets COVID-19 is only just beginning. There is no doubt that studies will rapidly accelerate over the next year and are sure to include the CLL patient’s response to vaccines. Dr. Lindsey Roeker of Memorial Sloan Kettering (MSK) in NYC moves the field forward
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
